Edberg v. CPI-The Alternative Supplier, Inc.

41 F. App'x 426
CourtCourt of Appeals for the Federal Circuit
DecidedJuly 16, 2002
DocketNo. 02-1008
StatusPublished
Cited by1 cases

This text of 41 F. App'x 426 (Edberg v. CPI-The Alternative Supplier, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Edberg v. CPI-The Alternative Supplier, Inc., 41 F. App'x 426 (Fed. Cir. 2002).

Opinion

DECISION

LOURIE, Circuit Judge.

Stephen C. Edberg, Stephen C. Ward-law, and Idexx Laboratories, Inc. (collectively, “Edberg”) appeal from the decision of the United States District Court for the District of Connecticut granting CPI-The Alternative Supplier, Inc.’s motion for summary judgment of noninfringement of Edberg’s U.S. Patents 5,780,259 and 5,429,933. Edberg v. CPI-The Alternative Supplier, Inc., 156 F.Supp.2d 190 (D.Conn. 2001) (“Edberg II”). Because the district court did not err, we affirm.

DISCUSSION

The ’259 and ’933 patents are both directed to a medium and method for detecting target bacteria in an environmental sample using a chemical “nutrient-indicator.” ’259 patent, col. 1, ll. 17-18; ’933 patent, col. 1, ll. 15-17. The nutrient-indicator, which cannot be consumed by non-target microbes in the sample, acts as both the primary nutrient for the targeted bacteria and, once metabolized, releases a moiety that alters a characteristic of the sample, such as its color. ’259 patent, col. 1, ll. 18-24; ’933 patent, col. 1, ll. 17-23. The medium, in addition to the nutrient-indicator, also contains varying amounts of amino acids, vitamins, and other ingredients.

Claim 9 of the ’259 patent and claim 10 of the ’933 patent are the only independent claims at issue in this appeal. Claim 9 reads as follows:

9. A method for detecting the presence or absence of a target microbe in an environmental or biological liquid sample, said method comprising the steps of:
a) mixing the liquid sample with a medium which includes an effective amount of vitamin, amino acid, element and salt ingredients operable to allow viability and log phase reproduction of said target microbe in the presence of a nutrient-indicator and to aid the target microbe through lag phase and into log phase of growth in the medium!sample mixture; and an effective amount of a nutrient-indicator which is provided in an amount sufficient to support log phase growth of said target microbe until a detectable characteristic signal is produced from said nutrient-indicator in the medium/sample mixture during said [428]*428log phase growth; said nutrient-indicator being incapable of supporting continued, logañthmic growth of any viable non-target microbes in the sample to produce a detectable characteristic signal; and said nutrient-indicator being operable to alter a detectable characteristic of the medium/sample mixture when metabolized by the target microbe so as to confirm the presence or absence of the target microbe in the sample; wherein said medium lacks a gelling agent so that when said medium is mixed with a liquefied sample a liquid is formed, and ivherein said ingredients and said nutrient-indicator are chosen such that growth of non-target microbes do not interfere with growth of said target microbe: and
b) thereafter evaluating the medium/sample mixture to determine whether said detectable characteristic has been altered, wherein the presence of said detectable characteristic indicates the presence of said target microbe in said sample and the absence of said detectable characteristic indicates the absence of said target microbe.

’259 patent, col. 8, I. 36 to col. 9, I. 3 (emphases added). Claim 10 is similar to claim 9 in all respects relevant to this appeal, ’933 patent, col. 9, ll. 24-60, and thus we will focus our analysis on the language of claim 9.

Edberg sued CPI in the district court, alleging that CPI’s Colitag™ testing medium infringed the ’259 and ’933 patents, as well as U.S. Patent 4,925,789, a related patent that is not at issue in the present appeal. Edberg v. CPI-The Alternative Supplier, Inc., 156 F.Supp.2d 190, 192 (D.Conn.2001). After holding a “Mark-man hearing,” the district court interpreted the claims of the ’789 patent to require that the medium used to detect target bacteria be a “specific medium,” i.e., a medium that is capable of supporting log-phase, reproductive growth of only the target microbes. Id. at 197. The court also determined that limitation to be present in the relevant claims of both the ’259 and ’933 patents based on the specifications and prosecution histories of those patents, despite the fact that the word “specific” is not found in any of those claims. Id. at 199-200. Based on that claim construction, the court granted CPI’s motion for summary judgment of noninfringement of all three patents because it determined that no reasonable juror could find that CPI’s Colitag™ product is a specific medium that permits substantial, log-phase growth of only target microbes. Id. at 202.

Edberg thereafter filed a motion for reconsideration, requesting that the district court either: (1) restrict the scope of its decision to the ’789 patent; or (2) modify that decision so as to indicate that genuine issues of material fact preclude the entry of summary judgment as to claim 9 of the ’259 patent. Edberg II 156 F.Supp.2d at -, at 1. The district court denied that motion, repeating its earlier conclusion that the intrinsic evidence of all three patents demonstrates that the “specific medium” limitation is “the essence of the ‘invention’ ” and thus is present in every claim at issue. Id. at -, 2. The court reconciled the absence of the term “specific” in claim 9 of the ’259 patent by recognizing the lack of inconsistency between the minor growth of non-target microbes during the initial lag phase, which claim 9 contemplates, and the log-phase, reproductive growth of those non-target microbes, which the specification and prosecution history of the ’259 patent expressly forbid. Id. at -, 4. Edberg appeals from the district court’s grant of summary judgment that CPI’s Colitag™ product does not infringe the ’259 and ’933 patents as a [429]*429matter of law. We have jurisdiction pursuant to 28 U.S.C. § 1295(a)(1).

Summary judgment is appropriate “if the pleadings, depositions, answers to interrogatories, and admissions on file, together with the affidavits, if any, show that there is no genuine issue as to any material fact and that the moving party is entitled to a judgment as a matter of law.” Fed.R.Civ.P. 56(c). “The evidence of the nonmovant is to be believed, and all justifiable inferences are to be drawn in his favor.” Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 255, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986). We review a district court’s grant of a motion for summary judgment de novo. Ethicon Endo-Surgery, Inc. v. United States Surgical Corp., 149 F.3d 1309, 1315, 47 USPQ2d 1272, 1275 (Fed.Cir.1998).

A determination of infringement requires a two-step analysis. “First, the court determines the scope and meaning of the patent claims asserted ... and then the properly construed claims are compared to the allegedly infringing device.” Cybor Corp. v. FAS Techs., Inc., 138 F.3d 1448, 1454, 46 USPQ2d 1169, 1172 (Fed. Cir.1998) (en banc) (citations omitted). Claim construction is an issue of law,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cisco Systems, Inc. v. Telcordia Technologies, Inc.
590 F. Supp. 2d 828 (E.D. Texas, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
41 F. App'x 426, Counsel Stack Legal Research, https://law.counselstack.com/opinion/edberg-v-cpi-the-alternative-supplier-inc-cafc-2002.